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Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is one of the most
common congenital birth defects. NSCL/P is a complex multifactorial disease caused
by interactions between multiple environmental and genetic factors. However, the
causal single nucleotide polymorphism (SNP) signature profile underlying the risk of
familial NSCL/P still remains unknown. We previously reported a 5.7-Mb genomic
region on chromosome 18q21.1 locus that potentially contributes to autosomal
dominant, low-penetrance inheritance of NSCL/P. In the current study, we performed
exome sequencing on 12 familial genomes (six affected individuals, two obligate
carriers, and four seemingly unaffected individuals) of a six-generation family to identify
candidate SNPs associated with NSCL/P risk. Subsequently, targeted bidirectional
DNA re-sequencing of polymerase chain reaction (PCR)-amplified high-risk regions of
MYO5B gene and sequenom iPLEX genotpying of 29 candidate SNPs were performed
on a larger set of 33 members of this NSCL/P family (10 affected + 4 obligate
carriers + 19 unaffected relatives) to find SNPs significantly associated with NSCL/P
trait. SNP vs. NSCL/P association analysis showed the MYO5B SNP rs183559995 GA
genotype had an odds ratio of 18.09 (95% Confidence Interval = 1.86–176.34; gender-
adjusted P = 0.0019) compared to the referenceGG genotype. Additionally, the following
SNPs were also found significantly associated with NSCL/P risk: rs1450425 (LOXHD1),
rs6507992 (SKA1), rs78950893 (SMAD7), rs8097060, rs17713847 (SCARNA17),
rs6507872 (CTIF ), rs8091995 (CTIF ), and rs17715416 (MYO5B). We could thus identify
mutations in several genes as key candidate SNPs associated with the risk of NSCL/P
in this large multi-generation family.
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INTRODUCTION
Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is
one of the most common congenital craniofacial birth defects
that accounts for 93–95% cases of Cleft Lip with or without Cleft
Palate (CL/P) and represents almost half of facial dysmorphology
(Stuppia et al., 2011). NSCL/P consists of isolated, nonspecific
malformations of the upper lip and oral cavity and is seen
frequently worldwide with average global incidence of 1.7 per
1000 live births and 1 per 700–1000 newborns in the United
States each year. Its effect on speech, hearing, appearance, and
cognition may cause long-term adverse effects on health and
social integration (Mossey et al., 2009). NSCL/P is amultifactorial
disease that exhibits a complex etiology due to interactions
between multiple genetic and environmental factors. Mutations
in several genes have been shown associated with increased
risk of NSCL/P in recent years including a causative variant
in the promoter region of IRF6 gene (chromosome 1q32.2)
(Rahimov et al., 2012; Leslie et al., 2015). Further, genome-wide
linkage analysis and genome-wide association studies (GWAS)
have identified and validated association of 13 different genetic
loci with the risk of NSCL/P (Leslie et al., 2015). However,
the evidences have been largely conflicting and therefore the
causal pathogenic variants underlying NSCL/P risk still remains
unknown.
Previously, we performed genome-wide linkage analysis on a
large multi-generational family of self-reported European origin
to identify a 5.7-Mb genomic region on chromosome 18q21.1
that potentially contains a pathogenic, high-risk variant for
NSCL/P (Beiraghi et al., 2007). We named this locus as OFC11
or orofacial cleft 11.
In the current study, we performed genetic fine-mapping of
the chromosome 18q21.1 region to home in on to the high risk
single nucleotide polymorphisms (SNPs) significantly associated
with the risk of NSCL/P. Exome sequencing was done on six
affected individuals, two obligate carriers, and four unaffected
individuals from the NSCL/P family that identified candidate
SNPs including multiple highly significant SNPs within the
gene MYO5B. Then, we performed targeted DNA resequencing
of MYO5B regions in the large six-generation NSCL/P family
to investigate the association of the most important genetic
variations and SNP-SNP interactions that may contribute to
NSCL/P disease etiology. Further, we performed sequenom
iPLEX genotyping on the SNPs that we found significant within
the 18q21.1 region by exome sequencing to validate in our larger
subset of familial NSCL/P subjects.
Our results identified SNPs within several genes in the 18q21.1
region as potentially pathogenic variants associated with high risk
of NSCL/P in this family.
MATERIALS AND METHODS
Study Subjects
Familial NSCL/P subjects included in the study are shown in the
pedigree provided in Figure 1. Affected individuals are shown
with blackened symbols, and unaffected individuals are shown
with open symbols. A dot in the center of a symbol denotes
an individual who is an obligate carrier and produced affected
children with NSCL/P. Samples included in the analysis are
marked with (∗∗) beside the pedigree symbols. Red (#) indicates
individuals who were exome sequenced. The study was approved
by the Institutional Review Board at the University of Minnesota.
DNA Isolation and Exome Sequencing
High-quality DNA was isolated from peripheral blood samples
obtained after informed consent from the family members of the
six-generation family (n= 33: 10 affected+ 4 obligate carriers+
19 unaffected relatives) using DNA-extraction kits, described
previously (Beiraghi et al., 2007).
Exome sequencing was performed on 12 genomes (six
affected individuals, two obligate carriers, and four unaffected
individuals) from the NSCL/P family using Illumina HiSeq with
TruSeq Exome Enrichment (Illumina, Inc., SanDiego, CA, USA).
Exome Analysis Pipeline
High-quality, binary alignment mapping (.bam) files were
generated by processing raw reads as described in the
PALEOMIX mapping pipeline (Supplementary Figure 1) which
independently processes and then combines both single and
paired end data (Li et al., 2009). Briefly, reads were filtered
for poor base call quality and adapter contamination using
Adapter Removal (Lindgreen, 2012). Filtered reads were mapped
to the HG19 human reference genome using Burrows Wheeler
Aligner 0.5.9 (BWA) (Li and Durbin, 2009). PCR duplicates
were removed and realignment was performed across detected
INDELs resulting in 31–54 million high-quality reads per
sample. Variants were called using both SAMtools and Genome
Analysis Toolkit (GATK) Unified Genotyper for all sites with >8
reads (Li et al., 2009; McKenna et al., 2010). Depth of
coverage was calculated using the coverage command in bedtools
version 2.25.0 with the features targeted by the TruSeq Exome
Enrichment platform. High quality variants were used as markers
in a GWAS study associating SNPs to the NSCL/P trait using the
PLINK whole genome association analysis toolset.
Variant Filtering
100 Western European (CEU) genomes from the 1000 Genomes
Project were utilized as unaffected controls (1000 Genomes
Project Consortium et al., 2012). Low quality variants (QUAL
< 50) called by GATK were removed and only the intersecting
variants between SAMtools and GATK were retained. Only
variants found in ≥6 affected individuals and ≤2 unaffected
individuals were included. Further, using the 1000 Genomes data,
variants with a minor allele frequency (MAF) >0.01 (1%) were
also removed. Subsequently, we annotated the variants using the
human reference database (GRCh37.75) with CADD, PolyPhen,
and snpEFF to identify the most likely destructive variants using
the following criteria: top 0.5% by CADD (scaled CADD score >
25) and “HIGH” designation by snpEFF (highly destructive effect
predicted) or a high confidence PolyPhen (damaging prediction).
In addition to the functional and clinical annotation (ClinVar),
for each variant, we also gathered information such as the
corresponding MAF in the 1000 genomes panel, the deleterious
effect prediction by dbSNP, and its association with phenotype
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FIGURE 1 | NSCL/P family pedigree. Affected individuals are shown with blackened symbols, and unaffected individuals are shown with open symbols. Samples
included in the analysis are marked with (**) beside their pedigree symbols. A dot in the center of a symbol indicates an individual who is an obligate carrier and
produced affected children with NSCL/P. Red (#) indicates those individuals exome sequenced as part of this study.
(odds ratio) (1000 Genomes Project Consortium et al., 2012;
Cingolani et al., 2012; Kircher et al., 2014; Landrum et al., 2014).
Primer Designing and DNA Sequencing
Primers were designed for PCR amplification of two separate
regions within the MYO5B gene at chr18:47349559–47350124
(566 bp) and chr18:47365313–47365672 (360 bp). Primer
designing was done using the PrimerSelect module of DNASTAR
Lasergene 11 Core Suite software (DNASTAR Inc., Madison,
WI) and oligos were synthesized at the University of Minnesota
Genomics Center (UMGC). Prior to oligo synthesis, the
primer sequences were verified using DNA BLAT and In-Silico
PCR tools available at the UCSC Genome Browser website
(https://genome.ucsc.edu/index.html) to avoid any nonspecific
DNA binding. PCR was performed in a 1X PCR buffer using
100 ng of genomic DNA, 10 pmol each of forward and
reverse primers, and GoTaq R© Colorless Master Mix (Promega
Corporation, Madison, WI, USA). Unincorporated nucleotides
and primers were removed prior to sequencing through
incubation with shrimp alkaline phosphatase and exonuclease
I (Affymetrix, Santa Clara, CA, USA) for 30 min at 37◦C and
inactivation at 80◦C for 15 min. Bi-directional DNA Sequencing
was performed with an ABI Prism 3700 automated sequencer
(Applied Biosystems, Foster City, CA) at the UMGC using
the PCR primers (forward and reverse) or internal primers
(sequence available on request). Sequences were assembled using
SeqMan, theMultiple Sequence Alignment module of DNASTAR
Lasergene 11 Core Suite software (DNASTAR Inc., Madison,
WI).
SNP Genotyping
Table 1 provides a detailed list of the SNP panel selected for
sequenom genotyping along with SNP inclusion criteria. A total
of 29 variants from 15 genes located within the chromosome
18q21.1 locus were genotyped in the NSCL/P DNA samples
using Sequenom iPLEX genotyping platform that uses MALDI-
TOF (matrix-assisted laser desorption ionization-time-of-flight
mass spectrometer)-based chemistry. Criteria for SNP selection
included MAF < 0.1 in 1000 Genomes project and Odds Ratio
≤0.5 or ≥3 from our exome sequencing data analysis.
Genotype-Phenotype Association Analysis
Genotype and allele frequencies were calculated and SNP
data was analyzed for association with NSCL/P risk using
a combination of the softwares Haploview 4.2 and snpStats
using gender as a covariate. SNPStats is a software application
that performs genotype-phenotype association analysis based
on linear or logistic regression according to the response
variable and calculates raw and adjusted odds ratios along with
corresponding 95% confidence intervals (Sole et al., 2006). All
statistical tests were two-sided; p < 0.05 was used as level of
significance.
RESULTS
Exome Sequencing Identified High Risk
Variants within Genes in 18q21.1 Region
Exome sequencing was used to examine expressed portions
of 12 familial genomes. Raw exome reads were sequenced
and mapped to the hg19 human reference genome using
a protocol targeting high-quality mapping confirmation in
individuals prior to variant discovery. Regions targeted by exome
sequencing averaged 38X coverage indicating sufficient read
depth to accurately discover SNPs. Variants were called using
both SAMtools (862,091 variants) as well as GATK (2,174,723
variants) in order to assess consensus between the two callers
and to account for possible differences due to arbitrary program
parameters. A total of 788,916 high-quality variants were in
the intersection between GATK and SAMtools which were
prioritized and kept for subsequent analysis. Seven hundred
and forty seven variants were within chr18q21.1 region, called
by both Broad’s GATK (864 variants) and SAMtools (1643
variants). Among these variants, 200 SNPs remained after
genotype quality control (GATK QUAL > 50 and sample
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TABLE 1 | List of SNPs selected for Sequenom iPLEX genotyping.
Sl. No. Variation name Location (bp) Gene
1 rs959655 chr18:52352494 DCC
2 rs728683 chr18:51582627
3 rs8097060 chr18:50458806
4 rs6507992 chr18:50382186 SKA1
5 rs11555886 chr18:50286217 CXXC1
6 rs17715416 chr18:49962255 MYO5B
7 rs17713847 chr18:49849792 SCARNA17
8 rs183559995 chr18:49839074 MYO5B
9 rs78201339 chr18:49823406 MYO5B
10 rs34474737 chr18:49562285 LIPG
11 rs3764482 chr18:48942576 SMAD7
12 rs78950893 chr18:48942348 SMAD7
13 rs8091995 chr18:48862698 CTIF
14 rs6507872 chr18:48862073 CTIF
15 rs11082655 chr18:48149234 ZBTB7C
16 rs1787187 chr18:47841113 SMAD2
17 rs1792666 chr18:47836843 SMAD2
18 rs1981 chr18:47834620 SMAD2
19 rs2510019 chr18:47028941 TCEB3B
20 rs328145 chr18:46593486 LOXHD1
21 rs435770 chr18:46571932 LOXHD1
22 rs17690358 chr18:46559258 LOXHD1
23 rs1450425 chr18:46529070 LOXHD1
24 rs188269968 chr18:46518017 LOXHD1
25 rs8095374 chr18:46213522 C18orf25
26 rs28699609 chr18:46094913 ATP5A1
27 rs2298787 chr18:46090014 ATP5A1
28 rs8092674 chr18:46086016 ATP5A1
29 rs10468858 chr18:45997899 PSTPIP2
Chromosomal locations are based on human genome hg19 (GRCh37) Assembly.
coverage rate>50%; seeMaterials andMethods Section). This set
of variants were computationally annotated by using the human
database GRCh37.75 with snpEff/SnpSif (Cingolani et al., 2012)
and tested for association with NSCL/P. Supplementary Table
1 lists all variants in the 18q21 region that appear at sufficient
frequency in this family (at least six family members have the
alternative allele regardless of their CLP status) regardless of their
1000 genomes allele frequency. SNPs were sorted based on their
estimated odds ratio given the affected/unaffected distinction,
with those conferring the highest risk at the top. Nearly 20%
(40 out of 200) of top SNPs associated with NSCL/P risk in this
family within the previously described 18q21.1 locus belonged to
the gene MYO5B. Other major genes at 18q21.1 that contained
high-risk variants include SMAD7, LOXHD1, SKA1, and
SCARNA17.
Targeted Resequencing and Fine Mapping
of MYO5B Regions
To further characterize the MYO5B locus, targeted bidirectional
Sanger DNA re-sequencing was performed for the MYO5B
gene regions harboring the four high-risk variants,
chr18:47349559+47350124 (contains the SNPs rs75335611,
rs117972198, rs372605995) and chr18:47365313+47365672
(contains rs183559995) on the larger subset of all 33 family
members from the six-generation family. A total of 71 genetic
variants were identified including 9 indels (insertion-deletions)
and 15 SNPs already reported in dbSNP database (Table 2).
Eighteen SNPs had minor allele frequencies >25%. Among the
variants that were found to be significant in exome sequencing,
the SNPs rs75335611, rs117972198, rs372605995 did not
significantly segregate with either the affected or unaffected
state. Whereas, variant 4 (chr18: 47365444, shown below),
which has been reported in dbSNP database (rs183559995) at a
population frequency of 0.017 was significantly associated with
the affected phenotype. Compared to the GG genotype used
as reference, the heterozygous rs183559995 GA genotype had
an odds ratio (ORGG vs. GA) of 18.09 [95% Confidence Interval
(CI) 1.86–176.34; gender-adjusted p = 0.0019]. Furthermore,
analysis of SNP-SNP interactions showed statistically significant
(Wilcoxon p < 0.05) NSCL/P risk due to the combined effects of
the mutant genotype of rs183559995 (GA) and mutant genotype
of any of the followingMYO5B SNPs rs201748833, rs368561623,
rs369480218, rs373003146, rs375226833, rs375530149, or
rs75335611 (data not shown).
Bioinformatics Analysis of rs183559995
(MYO5B)
Due to proximity of the MYO5B SNP rs183559995 to the
exon/intron junction, we used the web-based splice site
prediction software Exonic splicing enhancer (ESE) finder to
predict whether the mutant allele disrupts the binding of splice
site proteins. ESE finder screens for the potential splice sites
and binding affinities for the four main serine/arginine (SR)-rich
splicing factors (SRSFs): SF2/ASF, SC35, SRp40, and SRp55,
(Cartegni et al., 2003). Compared to the wild type allele (A),
the mutant allele (G) showed loss of binding site for SRSF1
(IgM-BRCA1) and gain in SRSF2 and SRSF6 binding sites. No
change was observed for the binding site of splicing factor
SRSF5.
SNP Genotyping and Genotype-Phenotype
Association Analysis
Table 3 provides results from analysis of association between
SNPs found present in Sequenom iPLEX genotyping assay with
the risk of NSCL/P in the family. Estimation of q-values, the
false discovery rate (FDR)-based measure of significance for
multiple hypothesis tests, was performed using Bioconductor’s
q-value package in R version 3.2.3 (https://cran.r-project.org/)
(Storey, 2002). The detailed results for the significantly associated
SNPs, including genotype and allele frequencies (Table 4) and
results from genotype-phenotype association analysis between
SNPs vs. NSCL/P risk, represented in terms of odds ratios
of mutant genotypes (Table 5), were obtained using snpStats
software. Results from the analysis of association of candidate
variants genotyped in this larger set of NSCL/P family
samples (n = 33) showed significant risks associated with the
mutant genotypes of rs1450425 (LOXHD1), rs6507992 (SKA1),
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TABLE 2 | List of dbSNPs identified using DNA re-sequencing of MYO5B regions.
Sl. No. SNP ID chr:position (bp) Alleles Consequence to transcript
1 rs112057683 chr18:49823471 G/A intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
2 rs113215300 chr18:49823369 G/T intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
3 rs115116077 chr18:49823552 G/A intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
4 rs116888891 chr18:49823561 C/A intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
5 rs144518115 chr18:49823548 T/C intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
6 rs148796775 chr18:49823549 G/A intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
7 rs201748833 chr18:49823258 T/C intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
8 rs368561623 chr18:49823263 A/G intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
9 rs369480218 chr18:49823644 T/C intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
10 rs372278198 chr18:49823313 C/T intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
11 rs373003146 chr18:49823646 A/T intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
12 rs375226833 chr18:49823643 C/A intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
13 rs375530149 chr18:49823314 C/G intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
14 rs75335611 chr18:49823283 C/T intron_variant/ NMD_transcript_variant/ 3_prime_UTR_variant
15 rs183559995 chr18:49839074 G/A upstream_gene_variant/ intron_variant
Chromosomal locations are based on human genome hg19 (GRCh37) Assembly.
TABLE 3 | Results from analysis of association between SNPs genotyped
vs. NSCL/P risk in the family.
SNP ID Gene name Associated allele Chi square q-value
rs2298787 ATP5A1 T 1.537 0.173
rs28699609 ATP5A1 A 1.537 0.173
rs8092674 ATP5A1 C 1.133 0.191
rs8095374 C18orf25 T 1.164 0.191
rs6507872 CTIF T 4.592 0.045
rs8091995 CTIF T 4.592 0.045
rs11555886 CXXC1 C 0.529 0.293
rs959655 DCC G 0.166 0.307
rs34474737 LIPG T 0.283 0.297
rs188269968 LOXHD1 T 12.060 0.006
rs1450425 LOXHD1 C 3.094 0.089
rs435770 LOXHD1 C 1.248 0.191
rs17690358 LOXHD1 C 0.388 0.297
rs328145 LOXHD1 C 0.269 0.297
rs17715416 MYO5B G 5.770 0.045
rs183559995 MYO5B A 5.070 0.045
rs78201339 MYO5B G 0.001 0.391
rs10468858 PSTPIP2 C 0.162 0.307
rs17713847 SCARNA17 A 6.371 0.045
rs6507992 SKA1 G 6.207 0.045
rs1792666 SMAD2 T 0.141 0.307
rs1981 SMAD2 G 0.060 0.337
rs78950893 SMAD7 T 5.070 0.045
rs3764482 SMAD7 A 2.012 0.147
rs2510019 TCEB3B C 3.148 0.089
rs11082655 ZBTB7C G 0.320 0.297
rs8097060 A 2.560 0.112
rs728683 A 0.422 0.297
rs78950893 (SMAD7), rs8097060, rs17713847 (SCARNA17),
rs6507872 (CTIF), rs8091995 (CTIF), rs183559995 (MYO5B),
rs17715416 (MYO5B). The SNP rs78950893 within SMAD7
gene showed the highest association with NSCL/P phenotype.
Compared to the reference genotype rs78950893 CC, the mutant
genotypes combined (CT+TT) presented an OR of 22.69 (95%
CI = 2.19–234.94; gender-adjusted p = 0.001). The SKA1
rs6507992 GG genotype displayed a very high OR of 15.41
(95% CI = 1.32–179.97; gender-adjusted p = 0.013) when
compared to the genotypes rs6507992 AA+GA combined. The
SNP rs8097060, located within a gene desert in chromosome
18q21.1 and flanked by the genes SKA1 and MAPK4, also
showed high risk association. When combined, the genotypes
rs8097060 AG and AA had an OR of 11.27 (95% CI =
1.17–108.20; gender-adjusted p = 0.0110) compared to the
reference genotype (GG). On the other hand, the LOXHD1
SNP rs1450425 showed an inverse association. Presence of the
heterozygous rs1450425 CT genotype had reduced NSCL/P risk
compared to the reference rs1450425 CC genotype (OR = 0.09;
95%CI = 0.01–0.95; gender-adjusted p = 0.017). Additionally
the SNPs rs17713847 (SCARNA17), rs17715416 (MYO5B) and
the CTIF SNPs rs6507872 and rs8091995 showed significant
association (p < 0.05) with NSCL/P when log-additive models
were considered.
DISCUSSION
Genetic variations have long been considered involved in the risk
of syndromic and nonsyndromic CL/P.Mutations in a number of
genes have shown promising associations including transcription
factors (IRF6, MSX1, TBX22), growth factors (TGFA, TGFb3),
xenobiotic metabolism genes (CYP1A1, GSTM1, NAT2), and
genes involved in immune response (PVRL1), although the
results have been conflicting (Ardinger et al., 1989; Hecht et al.,
Frontiers in Genetics | www.frontiersin.org 5 May 2016 | Volume 7 | Article 88
Mitra et al. Fine-Mapping of 18q21.1 Region
TABLE 4 | Details of allele and genotype frequencies of the significant SNPs genotyped in NSCL/P family members obtained using snpStats.
SNP Gene Alleles (n = 66) Genotypes (n = 33)
Control NSCL/P Control NSCL/P
Allele Count (Proportion) Count (Proportion) Genotype Count (Proportion) Count (Proportion)
rs1450425 LOXHD1 C 33 (0.75) 17 (0.94) C/C 11 (0.5) 8 (0.89)
T 11 (0.25) 1 (0.06) C/T 11 (0.5) 1 (0.11)
rs6507992 SKA1 A 30 (0.68) 7 (0.35) A/A 9 (0.41) 1 (0.1)
G 14 (0.32) 13 (0.65) A/G 12 (0.55) 5 (0.5)
G/G 1 (0.05) 4 (0.4)
rs78950893 SMAD7 C 36 (0.82) 11 (0.55) C/C 15 (0.68) 1 (0.1)
T 8 (0.18) 9 (0.45) C/T 6 (0.27) 9 (0.9)
T/T 1 (0.05) 0 (0)
rs183559995 MYO5B G 38 (0.83) 11 (0.55) G/A 8 (0.35) 9 (0.9)
A 8 (0.17) 9 (0.45) G/G 15 (0.65) 1 (0.1)
rs8097060 G 33 (0.75) 11 (0.55) A/A 1 (0.05) 0 (0)
A 11 (0.25) 9 (0.45) G/A 9 (0.41) 9 (0.9)
G/G 12 (0.55) 1 (0.1)
rs17713847 SCARNA17 G 30 (0.68) 6 (0.33) A/A 4 (0.18) 3 (0.33)
A 14 (0.32) 12 (0.67) G/A 6 (0.27) 6 (0.67)
G/G 12 (0.55) 0 (0)
rs17715416 MYO5B A 27 (0.61) 5 (0.28) A/A 9 (0.41) 0 (0)
G 17 (0.39) 13 (0.72) A/G 9 (0.41) 5 (0.56)
G/G 4 (0.18) 4 (0.44)
rs6507872 CTIF C 32 (0.73) 9 (0.45) C/C 11 (0.5) 0 (0)
T 12 (0.27) 11 (0.55) C/T 10 (0.45) 9 (0.9)
T/T 1 (0.05) 1 (0.1)
rs8091995 CTIF G 32 (0.73) 9 (0.45) G/G 11 (0.5) 0 (0)
T 12 (0.27) 11 (0.55) G/T 10 (0.45) 9 (0.9)
T/T 1 (0.05) 1 (0.1)
1991; Chenevix-Trench et al., 1992; Vintiner et al., 1992, 1993;
Stein et al., 1995; Wyszynski et al., 1997; Lidral et al., 1998;
Martinelli et al., 1998; Vieira et al., 2005; Alkuraya et al.,
2006; Kerameddin et al., 2015). In addition, recent genomewide
association studies have identified 13 different chromosomal loci
that may harbor common variants associated with increased risk
of NSCL/P including 1p22, 1p36, 2p21, 3p11.1, 8q21.3, 8q24,
9q22, 10q25, 15q22, 17p13, 17q22, and 20q12 (Birnbaum et al.,
2009; Grant et al., 2009; Marazita et al., 2009; Beaty et al.,
2010; Mangold et al., 2010; Ludwig et al., 2012; Leslie et al.,
2015).
However, despite the progress in gene identification for
NSCL/P, a reliable high risk mutation signature that underline
the mechanisms behind the development of NSCL/P have yet to
be identified.
In a previous study, we used SNP array to perform genome-
wide linkage analysis on DNA isolated from peripheral blood
samples from a large multigenerational family of self-reported
European origin to investigate the role of genetic variants
toward NSCL/P risk (Beiraghi et al., 2007). The SNP array
(GeneChip Mapping 10K XbaI Array) consisted of 10,555 SNPs
equally distributed in the genome, with mean intermarker
distances of 250 kb and an average heterozygosity of 0.38.
Our genome wide genotyping study identified a 5.7-Mb
genomic region on chromosome 18q21.1 spanned by proximal
marker rs1824683 (42,403,918 bp) and distal marker rs768206
(48,132,862 bp) that potentially contains a pathogenic, high-risk
variant signature associated with NSCL/P in this family (Beiraghi
et al., 2007).
In the current study, we performed fine-mapping of the
18q21.1 region using exome sequencing to identify novel rare
pathogenic variants significantly associated with NSCL/P risk.
Among the SNPs that conferred the highest risk in exome
sequencing, a large number of top candidate variants belonged
to the gene MYO5B (Chr18: 47349155–47721451), a myosin
family member which is involved in protein trafficking, neuronal
morphogenesis, cell signaling, vesicular trafficking, plasma
membrane recycling and epithelial polarization. Mutations in the
MYO5B gene have been previously implicated in human diseases
including microvillus inclusion disease (MVID) in newborns
(Knowles et al., 2014).
Subsequently, targeted re-sequencing of these high-risk
MYO5B gene regions provided strong evidence that the SNP
rs183559995 (G/A) in MYO5B is a strong candidate genetic
risk variant for NSCL/P in this family. Although, rs183559995
is an intronic variant whose function has not been described,
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TABLE 5 | Results for the SNPs found significant using snpStats in the genotype-phenotype association analysis between SNPs vs. NSCL/P risk,
represented in terms of odds ratios of mutant genotypes.
Association with NSCL/P
Crude analysis Adjusted by sex
SNP Gene Model Genotype OR (95% CI) P-value OR (95% CI) P-value
rs1450425 LOXHD1 C/C 1 0.0320 1 0.0170
C/T 0.13 (0.01–1.17) 0.09 (0.01–0.95)
rs6507992 SKA1 Recessive A/A-G/A 1 0.0130 1 0.0130
G/G 14.00 (1.31–150.03) 15.41 (1.32–179.97)
Log-additive — 6.10 (1.30–28.58) 0.0065 6.68 (1.35–32.94) 0.0054
rs78950893 SMAD7 Dominant C/C 1 0.0013 1 0.0010
T/C-T/T 19.29 (2.03–183.42) 22.69 (2.19–234.94)
Log-additive — 7.09 (1.30–38.67) 0.0099 8.48 (1.47–48.84) 0.0062
rs183559995 MYO5B G/G 1 0.0021 1 0.0019
G/A 16.87 (1.80–158.06) 18.09 (1.86–176.34)
rs8097060 Dominant G/G 1 0.0110 1 0.0110
A/G-A/A 10.80 (1.16–100.43) 11.27 (1.17–108.20)
Log-additive — 4.53 (0.87–23.62) 0.0480 4.41 (0.82–23.62) 0.0560
rs17713847 SCARNA17 Log-additive — 3.66 (1.11–12.01) 0.0190 4.77 (1.26–18.09) 0.0089
rs17715416 MYO5B Log-additive — 4.11 (1.12–15.12) 0.0180 6.14 (1.29–29.30) 0.0065
rs6507872 CTIF Log-additive — 9.39 (1.16–75.97) 0.0070 17.62 (1.80–172.46) 0.0015
rs8091995 CTIF Log-additive — 9.39 (1.16–75.97) 0.0070 17.62 (1.80–172.46) 0.0015
predictions using ESEFinder indicate that presence of the mutant
allele (A) has the potential to disrupt binding of splicing factors.
Further, SNP-SNP interaction analysis showed statistically
significant increase in NSCL/P risk due to the combined effects
of the presence of rs183559995 (A) along with mutant alleles
of these MYO5B SNPs rs201748833, rs368561623, rs369480218,
rs373003146, rs375226833, rs375530149, or rs75335611. In
addition, we also found another MYO5B SNP, rs17715416 that
showed significant association with NSCL/P (gender-adjusted
Plog−additive model = 0.0065).
To look more into the interactions of the MYO5B gene,
we used GIANT (Genome-scale Integrated Analysis of gene
Networks in Tissues), a webserver-based system that integrates
human genomic data to build functional networks with edges
supported by various types of interaction or co-expression
evidence (Greene et al., 2015). Interestingly, while looking into
the neighbors of MYO5B using GIANT (Figure 2), we observed
a network containing a set of functional neighbors forMYO5B is
enriched for the KEGG “Epithelial tight junction” pathway. This
was mainly driven by its similarity to members of this pathway
including TJP3, MYH14, EPB41L1, LLGL2 suggesting that
MYO5B may play a role here. This seems to have some support
from more focused studies as well. For instance, an earlier study
on MVID—a form of congenital enteropathy, indicates that the
expression of MYO5B-P660L (an MVID-associated mutation
found within Navajo populations) in patients with MVID
resulted in global changes in polarity at the villus tips that could
lead to a number of complications including aberrant junctions,
and losses in transcellular ion transport pathways (Knowles
et al., 2014). It is of considerable interest to note that epithelial
tight junctions are of relevance to cleft lip/palate and that
aberrant junctions have been previously implicated in NSCL/P.
For example, mutations in PVRL1 (nectin-1), which plays a
key role in adherens junctions, have previously been associated
with cleft lip/palate (Sozen et al., 2001). This combination
of evidence strengthens the potential connection between the
MYO5B mutations and tight junctions, which might eventually
influence NSCL/P risk. Additional studies will be required to
determine significance with regard to MYO5B structure and
function in NSCL/P pathology.
Furthermore, we performed genotyping of 29 SNPs included
from the 18q21.1 region to identify additional genetic variants
associated with NSCL/P risk. The p-values from logistic
regression analysis were gender-adjusted to account for the
gender-based differences in prevalence. SNP genotyping
studies found the mutant genotypes of the following SNPs
were associated with NSCL/P risk: rs78950893 (SMAD7),
rs1450425 (LOXHD1), rs6507992 (SKA1), rs8097060, rs17713847
(SCARNA17), rs6507872 (CTIF), rs8091995 (CTIF), and
rs17715416 (MYO5B). Inhibition of SMAD pathway by all-trans
retinoic acid (atRA) have previously been implicated in cleft
palate. It was shown that atRA-induced inhibition of SMAD
pathway played important role in the degradation of the basal
laminin within the midline epithelial seam (MES) which might
contribute to failure of palatal fusion (Wang et al., 2011).
In our study, the combined mutant genotype (CT+TT) of
the SMAD7 SNP rs78950893 showed the highest association
with NSCL/P phenotype (ORCT+TT vs. CC = 22.69; 95% CI =
2.19–234.94; gender-adjusted p = 0.001). In contrast, the
heterozygous LOXHD1 rs1450425 CT genotype was found
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FIGURE 2 | Functional network built using GIANT (Genome-scale Integrated Analysis of gene Networks in Tissues) showing neighbors of MYO5B.
positively associated with NSCL/P risk. LOXHD1 codes for
a highly conserved conserved stereociliary protein involved
in targeting proteins to the plasma membrane. LOXHD1
mutations have been previously implicated in the genetic
etiology of autosomal recessive nonsyndromic hearing loss
(ARNSHL) (Atik et al., 2015). Among the other genes found
significant, spindle- and kinetochore-associated protein 1
(SKA1) is a microtubule-binding protein that localizes to spindle
microtubule and the outer kinetochore interface during mitosis
and is therefore essential for proper chromosome segregation
(Li et al., 2014). In our study, SKA1 SNP rs6507992 showed
highly significant association with the NSCL/P phenotype,
rs6507992 GG had an odds ratio of 15.41 compared to the
rs6507992 AA and GA genotypes combined (ORAA+GA vs. GG =
15.41; 95% CI = 1.32–179.97; gender-adjusted p = 0.0130).
CBP80/20-dependent translation initiation factor (CTIF) is
a component of the CBP80 translation initiation complex
that binds cotranscriptionally to the cap end of nascent
mRNA, recognizes premature termination codons (PTCs)
in mRNAs and directs nonsense-mediated decay (NMD) in
PTC-containing mRNAs. SNPs in CTIF have been shown
to be associated with hearing function in children (Harrison
et al., 2015). We found two SNPs in CTIF gene (rs6507872
and rs8091995) with statistically significant association with
NSCL/P risk (gender-adjusted Plog−additive model = 0.0015, for
both).
Exome sequencing of this family showed several loci with
co-segregating variants associated with NSCP/P. This relatively
small cohort of 12 individuals, even when cross referencing
variants observed within the 1000 genomes, poses several
difficulties. First, the low penetrance of the disease confounds
case/control status for several of the individuals within the
family (Figure 1). Second, targeted exome sequencing assumes
adequate depth of coverage to detect causal mutations and,
additionally, does not account for larger structural variation
such as insertions or deletions that could potentially be causing
the phenotype. However, given the number of SNPs which had
high odds ratios in the gene MYO5B, fine mapping through
targeted resequencing was performed of this region in a larger
familial cohort to supplement variants discovered by whole
exome sequencing. Using fine-mapping of the chromosome
18q21.1 region, we could identify SNPs that are strong candidates
for association with familial NSCL/P risk. Further studies
are required in terms of linkage disequilibrium analysis and
functional genomics to determine the extent of significance of
these high risk variants vis-à-vis gene function and role in the
complex genetic etiology of NSCL/P. Moreover, low penetrance
of NSCL/P in this family suggests a multigenic model which
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will require identification of additional variants, analysis of
potential copy number variation (CNV) burden from the exome
data and further studies in larger sets of families/pedigrees
to derive a robust high-risk SNP signature profile associated
with NSCL/P.
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